MRKR — Marker Therapeutics Share News
0.000.00%
Last trade - 00:00- $16.01m
- $4.68m
- $3.55m
Brief: Marker Therapeutics Provides A Clinical Update On MT-601 In Patients With Lymphoma
Marker Therapeutics slides after $16 mln private placement
Brief: Marker Therapeutics Awarded $9.5 Mln Grant From The Cancer Prevention & Research Institute Of Texas (Cprit)
Brief: Marker Therapeutics Files For Mixed Shelf Of Up To $300 Million
Marker Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Marker Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: Marker Therapeutics Awarded $2 Mln Grant From NIH
Marker Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Marker Therapeutics Delivers Notice To Lincoln Park Capital Fund
Brief: Marker Therapeutics Receives Approval From U.S. Adopted Name Council And International Nonproprietary Names Expert Committee For “Neldaleucel” As Nonproprietary Name For MT-601
Brief: Marker Therapeutics Announces Clinical Program Updates
Brief: Marker Therapeutics Announces Sustained Complete Response In First Lymphoma Patient Treated With MT-601 Following Car T Relapse
Brief: Marker Therapeutics Announces Complete Response In First Lymphoma Patient Treated With MT-601 After Car T Relapse
Brief: Marker Therapeutics Q2 net income USD 2.515 million
Brief: Marker Therapeutics Updates On Clinical Readiness For MT-401 Off-The-Shelf Program
U.S. STOCKS ON THE MOVE-Novavax, Domino's Pizza, Fox Corp
U.S. STOCKS ON THE MOVE-Hecla Mining, Shineco, Fulcrum Therapeutics
Marker Therapeutics gains on EMA's 'orphan drug' tag for blood cancer therapy
Marker Therapeutics up on EMA's 'orphan drug' tag for blood cancer therapy